SCHEMBL92319

SCHEMBL92319

CCc1noc(-c2ccccc2OC)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.58
NPC1 O15118 12/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
NPSR1 Q6W5P4 3/20 0.58
TDP1 Q9NUW8 1/20 0.58
SMN1; SMN2 Q16637 13/20 0.57
GAA P10253 2/20 0.57
TP53 P04637 9/20 0.56
HSD17B10 Q99714 8/20 0.56
KDM4E B2RXH2 7/20 0.56
PKM P14618 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
ALDH1A1 P00352 7/20 0.54
TSHR P16473 3/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 1/20 0.54
HPGD P15428 4/20 0.53
MEN1 O00255 2/20 0.53
NFKB1 P19838 2/20 0.53
NFKB2 Q00653 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379161 0.86 RAB9A (0.60) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL13461952 0.86 RAB9A (0.57) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL10202917 0.84 RAB9A (0.55) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL4375583 0.79 L3MBTL1 (0.70) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL5660762 0.79 RAB9A (0.61) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL17055748 0.78 NPC1 (0.43) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL5660757 0.78 RAB9A (0.60) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL18611858 0.78 NPC1 (0.54) RAB9ANPC1L3MBTL1NPSR1TDP1
SCHEMBL18610908 0.78 NPC1 (0.58) RAB9ANPC1L3MBTL1TDP1SMN1; SMN2
SCHEMBL3035463 0.76 NPC1 (0.51) RAB9ANPC1L3MBTL1NPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-04 US disclosed
US-9079901-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-07-14 US disclosed
US-20150080370-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2015-03-19 US disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-8703759-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2014-04-22 US disclosed
US-8129415-B2 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2012-03-06 US disclosed
US-20090192196-A1 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080370-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, CACNA1E RAB9A 1114/4885NPC1 903/4885L3MBTL1 3585/4885
US-20090192196-A1 Fungicide hydroximoyl-tetrazole derivatives HAAO, HAO1, CYP51A1 RAB9A 3465/4885NPC1 3856/4885L3MBTL1 428/4885
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 RAB9A 2388/4885NPC1 1431/4885L3MBTL1 2918/4885
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 RAB9A 2715/4885NPC1 1972/4885L3MBTL1 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.